2022
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.Peer-Reviewed Original ResearchConceptsPD-L1 positivityPD-L1 protein expressionPD-L1 expressionGrade 3 cancersPD-L1TIL scoreTumor gradeMultivariate analysisHigher PD-L1 positivityTumor-infiltrating lymphocyte countsConclusionPD-L1 expressionProtein expressionPD-L1 immunohistochemistryChi-square testResultsPD-L1T1 cancersLymphocyte countT3 tumorsIndependent predictorsTumor sizeLarge tumorsPositivity rateCell positivityBreast cancerGrade 2
2019
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal Of Clinical Oncology 2019, 37: 3484-3492. PMID: 31657982, PMCID: PMC7194448, DOI: 10.1200/jco.19.00693.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesTriple-negative breast cancerDisease-free survivalOverall survivalImmune response signaturesBreast cancerEarly-stage triple-negative breast cancerThree-year disease-free survivalParaffin-embedded tumor tissueThird of patientsTumor-infiltrating lymphocytesSubgroup of patientsCox regression modelResponse signatureAdjuvant ACAdjuvant doxorubicinSTIL densityT2N0 diseaseAC chemotherapyNodal statusPrognostic roleImproved prognosisPrognostic valueTumor sizePrognostic marker
2018
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. PMID: 29372234, PMCID: PMC5885272, DOI: 10.1001/jamaoncol.2017.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantEligibility DeterminationFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPatient SelectionPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsResearch DesignRetrospective StudiesRisk FactorsSurvival AnalysisTrastuzumabTumor BurdenWatchful WaitingYoung AdultConceptsTumor sizeAdjuvant trialsEligibility criteriaNodal statusClinical trialsResidual riskEarly-stage breast cancerAdjuvant clinical trialsBaseline prognostic riskFuture adjuvant trialsResidual risk estimatesRisk of recurrenceBreast cancer therapyRisk thresholdTrial powerClinical trial powerTrial eligibilityAdjuvant therapyCare therapyConsecutive patientsPrognostic riskPatient eligibilityTrial populationPatient cohortControl arm
2015
Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database
Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. Journal Of The American College Of Surgeons 2015, 220: 1063-1069. PMID: 25868410, DOI: 10.1016/j.jamcollsurg.2015.02.011.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseNeoadjuvant chemotherapyBreast preservationBreast conservationTumor sizeCancer DatabaseDefinitive breast surgerySmall institutional seriesBreast cancer increasesAdvanced nodal diseaseInvasive breast cancerYounger patient ageBreast tumor sizeLarger tumor sizeMultivariate logistic regressionHigh tumor gradeAmerican Cancer SocietyAdjuvant chemotherapyNodal diseasePrimary surgeryT4 tumorsInstitutional seriesPatient ageRetrospective reviewDistant metastasis
2013
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
Kelly C, Beamish R, McCaffrey J, SMITH M, Crown J, O'Connor M, McGee S, O'Reilly S, Moylan E, Gonzalez-Angulo A, Litton J, Pusztai L, Kelly C. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Journal Of Clinical Oncology 2013, 31: 598-598. DOI: 10.1200/jco.2013.31.15_suppl.598.Peer-Reviewed Original ResearchRisk of recurrenceOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreClinicopathologic factorsBreast cancerRecurrence risk assessmentDistant recurrenceNode negativeIR groupOncotype DXRisk groupsHER-2 negative breast cancerHER2-negative breast cancerEarly-stage breast cancerProportion of patientsOncotype DX testingNegative breast cancerChemotherapy benefitNodal statusPatient chartsTumor sizeClinical trialsAcademic hospitalLR groupThe prognostic impact of age in patients with triple-negative breast cancer
Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Research And Treatment 2013, 138: 591-599. PMID: 23460246, DOI: 10.1007/s10549-013-2461-x.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerOverall survivalPrognostic impactTumor gradeBreast cancerPrimary triple-negative breast cancerMultivariate analysisSignificant independent prognostic variablesAggressive systemic therapyIndependent prognostic variablesPatients 31Median DFSClinical characteristicsEffect of ageSystemic therapyYounger patientsNodal stageTumor sizePathological parametersPoor survivalPrognostic variablesPatientsAge groupsAgeCancerClinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal Of Cancer 2013, 108: 285-291. PMID: 23299541, PMCID: PMC3566807, DOI: 10.1038/bjc.2012.557.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaBreast-conserving surgeryNeoadjuvant chemotherapyPure lobular carcinomaLobular carcinomaClinical benefitTumor sizeER-positive invasive ductal carcinomasLower pathological complete response rateResponse ratePathological complete response ratePathological response rateComplete response rateGood clinical responsePathological complete responseType of chemotherapyPositive surgical marginsSurgical resection marginsClinical responseNodal statusComplete responseResection marginsSurgical marginsDuctal carcinomaPositive margins
2012
Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping
Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis‐Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. The Breast Journal 2012, 18: 303-311. PMID: 22759093, DOI: 10.1111/j.1524-4741.2012.01264.x.Peer-Reviewed Original ResearchConceptsStage I carcinomaAdjuvant therapyBreast cancerGene prognostic signaturePatient ageTumor sizeImmunohistochemical markersIndividual patientsConsensus conferencePrognostic signatureSteroid hormonesMolecular profilingNottingham indexMolecular phenotypingPatientsCarcinomaTherapyCancerBreastPrognosisPart of decisionHormoneAssessment of method of breast cancer detection and Onco type DX recurrence score.
Kelly C, Parker I, McCaffrey J, Crown J, O'Connor M, McGee S, Pusztai L, Kelly C. Assessment of method of breast cancer detection and Onco type DX recurrence score. Journal Of Clinical Oncology 2012, 30: 581-581. DOI: 10.1200/jco.2012.30.15_suppl.581.Peer-Reviewed Original ResearchRecurrence scoreClinicopathological variablesBreast cancerLymph nodesHER-2 negative breast cancerSignificant associationHER2-negative breast cancerFavorable pathological characteristicsTraditional clinicopathological variablesScreen-detected cancersNumber of patientsDX recurrence scoreNegative breast cancerMethod of detectionOncotypeDX recurrence scoreLymphovascular invasionBetter prognosisInterval cancersPatient chartsRoutine careTumor sizePathological characteristicsPrognostic informationTumor gradeClinical trials12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)
Karn T, Hatzis C, Symmans W, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Holtrich U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set). Annals Of Oncology 2012, 23: ii18. DOI: 10.1016/s0923-7534(19)65684-x.Peer-Reviewed Original ResearchEndocrine therapyPositive patientsPrognostic valueTumor sizeER-positive primary breast cancerPositive primary breast cancerAdjuvant endocrine therapyNegative PgR statusNode-negative cohortPure prognostic valueNode-negative patientsStepwise Cox regressionER-positive patientsPrimary breast cancerBest independent predictorPgR statusAdjuvant treatmentRetrospective cohortIndependent predictorsLymph nodesNegative cohortSurvival benefitCox regressionClinical associationsHER2 status
2011
Systemic Adjuvant Therapy for Stage I Breast Cancer
Pusztai L, Kelly C. Systemic Adjuvant Therapy for Stage I Breast Cancer. 2011, 269-281. DOI: 10.1007/978-94-007-0489-3_11.Peer-Reviewed Original ResearchStage I breast cancerI breast cancerMultivariable prediction modelBreast cancerAdjuvant therapyHuman epidermal growth factor 2 (HER2) receptor statusER-positive breast cancerSystemic adjuvant therapyCo-morbid illnessLymph node statusNottingham Prognostic IndexBetter risk stratificationIndependent prognostic factorBreast cancer biologyBreast cancer subtypesClinical factorsLymphovascular invasionPrognostic factorsReceptor statusRisk stratificationNode statusPrognostic indexPrognostic valueTumor sizeHistological grade
2008
Histopathologic and Molecular Markers of Prognosis and Response to Therapy
Pusztai L, Symmans W. Histopathologic and Molecular Markers of Prognosis and Response to Therapy. MD Anderson Cancer Care Series 2008, 323-343. DOI: 10.1007/978-0-387-34952-7_11.Peer-Reviewed Original ResearchLymph node-negative breast cancerNode-negative breast cancerBreast cancerEndocrine therapyMultigene assaysValuable additional prognostic informationAdditional adjuvant chemotherapyPrognosis of womenAdjuvant endocrine therapyLymph node statusSurgical margin statusAdditional prognostic informationRoutine pathologic evaluationPersonalized treatment recommendationsAppropriate treatment decisionsAdjuvant chemotherapyMargin statusPathologic evaluationTrastuzumab therapyBetter prognosisNode statusOncotype DXTumor sizeHistopathologic subtypeProgesterone receptor
2007
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research 2007, 9: r87. PMID: 18086299, PMCID: PMC2246190, DOI: 10.1186/bcr1836.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, Fine-NeedleBreast NeoplasmsCD40 AntigensCyclophosphamideEpirubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoadjuvant TherapyNeoplasm StagingNeoplasm, ResidualPaclitaxelPredictive Value of TestsReceptor, ErbB-2RNA, MessengerSignal TransductionTranscription, GeneticTrastuzumabTreatment OutcomeUp-RegulationConceptsPathologic complete responseBreast cancerIIIA breast cancerFine-needle aspirationConcomitant paclitaxelConcomitant trastuzumabFEC therapyPreoperative trastuzumabPreoperative chemotherapyPrimary endpointComplete responseNodal statusResidual cancerTumor sizeTumor responseNuclear gradeReceptor mRNAMolecular predictorsTrastuzumabStage IIGreater riskLow expressionCancerCyclophosphamidePatients
2006
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006, 107: 1459-1466. PMID: 16948128, DOI: 10.1002/cncr.22177.Peer-Reviewed Original ResearchConceptsResidual tumor sizeBreast conservation therapyNeoadjuvant chemotherapyBreast conservation surgeryBreast cancer patientsTumor sizeConservation therapyBreast conservationConservation surgeryCancer patientsAnthracycline-based neoadjuvant chemotherapyD. Anderson Cancer CenterPaclitaxel neoadjuvant chemotherapyPreoperative chemotherapy regimenPreoperative chemotherapy regimensSuccessful conservative surgeryValidation of nomogramsInstitut Gustave RoussyAnderson Cancer CenterLogistic regression modelsChemotherapy regimenChemotherapy regimensConservative surgeryClinicopathologic dataCancer CenterImpact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer
Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals Of Surgery 2006, 124: 130-136. PMID: 16926572, PMCID: PMC1856540, DOI: 10.1097/01.sla.0000234897.38950.5c.Peer-Reviewed Original ResearchConceptsBreast-conserving therapyRe-excision ratesExtent of surgeryPreoperative chemotherapyInitial tumor sizeRandomized clinical trialsBreast operationsBreast cancerSurgical proceduresBCT patientsPostoperative chemotherapyBreast tissueTumor sizeClinical trialsRates of BCTProspective randomized clinical trialsFinal surgical procedureLarge breast tumorsConsecutive patientsExtensive resectionChemotherapyPatientsVolume of tissueBreast tumorsT1-T3Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy
Esteva F, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar A, Hortobagyi G, Symmans W, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy. Journal Of Clinical Oncology 2006, 24: 545-545. DOI: 10.1200/jco.2006.24.18_suppl.545.Peer-Reviewed Original ResearchBreast cancerOverall pathologic complete response ratePathologic complete response rateTrastuzumab-resistant cell linesAbsence of trastuzumabOnly preoperative chemotherapyComplete response rateReceptor mRNA expressionFine-needle aspirationConcomitant trastuzumabFEC chemotherapyPreoperative trastuzumabQuantitative estrogenCyclophosphamide chemotherapyPreoperative chemotherapyNodal statusResidual diseaseTumor sizeClinical variablesNuclear gradeNeedle aspirationPharmacogenomic predictorsMolecular predictorsResponse rateTrastuzumab
2004
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal‐Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004, 100: 1365-1373. PMID: 15042669, DOI: 10.1002/cncr.20134.Peer-Reviewed Original ResearchConceptsResidual tumor sizeCore needle biopsyNeoadjuvant chemotherapyTumor sizeResection specimensNeedle biopsyBreast carcinomaTumor cellularityClinical responsePathologic responseControl groupDiagnostic core needle biopsyGreatest dimensionPrimary surgical managementResidual primary tumorResidual tumor categoriesComplete pathologic responseWeeks of diagnosisResidual tumor groupEosin-stained tissue sectionsCyclophosphamide chemotherapyPartial responsePathologic assessmentPathologic evaluationPathologic size
2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. PMID: 14654548.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCell Cycle ProteinsCOP9 Signalosome ComplexCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMiddle AgedPeptide HydrolasesReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTime FactorsTranscription FactorsTumor Suppressor ProteinsConceptsNode-negative breast cancerAdjacent normal tissuesInvasive breast carcinomaBreast cancerJab1 overexpressionNormal tissuesBreast carcinomaAdjuvant systemic therapyDisease-free survivalIndependent prognostic factorInvasive breast cancerLow nuclear gradeBreast cancer tissuesExpression levelsProtein-1 expressionBreast tumor tissuesWestern blot analysisDomain-binding protein 1Patient agePrognostic factorsSystemic therapyPrognostic significanceTumor sizeNuclear gradeInvasive tumors
2001
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
Kuerer H, Singletary S, Buzdar A, Ames F, Valero V, Buchholz T, Ross M, Pusztai L, Hortobagyi G, Hunt K. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. The American Journal Of Surgery 2001, 182: 601-608. PMID: 11839324, DOI: 10.1016/s0002-9610(01)00793-0.Peer-Reviewed Original ResearchConceptsLocal-regional recurrence rateOperable breast cancerPrimary tumorBreast cancerTumor downstagingNeoadjuvant chemotherapyResidual carcinomaRecurrence rateStage III breast carcinomaStage IIComplete clinical responseCycles of chemotherapyMedian tumor sizeAxillary node dissectionBreast conservation surgeryNode dissectionClinical responseProspective trialSurgical resectionPalpable massSegmental resectionAdequate resectionPathologic examinationTumor sizeLarge tumorsExpression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry
Esteva F, Hortobagyi G, Sahin A, Smith T, Chin D, Liang S, Pusztai L, Buzdar A, Bacus S. Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology & Oncology Research 2001, 7: 171-177. PMID: 11692142, DOI: 10.1007/bf03032345.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerHER-2Mitogen-activated protein kinaseQuantitative immunohistochemistryHER-4Frequency of expressionGrowth factor receptorHER-3Early-stage breast cancerFactor receptorHormone receptor statusInvasive breast cancerErbB/Breast cancer tissuesExpression of EGFRYears of ageEvidence of associationReceptor statusLymph nodesTumor sizeHER familyTumor markersTumor specimensCancer tissues